Stem cell research leads to a trial of an epilepsy drug for ALS
Until recently, most scientific knowledge about amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease, came from mouse studies. But new research is taking this incurable neurodegenerative condition to the dish, tapping induced pluripotent stem cells (iPS cells)—made from ALS patients’ skin cells—to create motor neurons. These motor neurons are being used not just [Read More]
RNAi isn’t ready to be silenced
RNA interference (RNAi) is a therapeutic technology that blocks gene expression with either small interfering RNAs (siRNA) or microRNAs (miRNA). RNAi’s discovery was considered transformative enough to earn the 2006 Nobel Prize for Physiology or Medicine, but from the start the challenge of delivering RNA-silencing therapeutics to the right tissues has hobbled efforts to use [Read More]
Who We are
The mission of the Technology and Innovation Development Office (TIDO) is to translate the excellence of the laboratory research and clinical care at Children’s Hospital Boston into lifesaving biomedical products, devices and procedures for the public benefit.
News and Events
Pfizer CTI/Boston Children's collaboration program: Pre-proposals due May 16
Pfizer CTI is now conducting a call for proposals at Boston Children’s. Non confidential pre-proposals are due May 16, 2014!
Shire/Boston Children's rare disease collaboration program: Pre-proposals due May 1
The second cycle of the collaboration program between Shire and Boston Children’s, which provides funding and additional in kind resources to support the development of therapeutics for rare diseases, was officially launched on April 1.
TIDO's 2013 Annual Report Released!
TIDO reached new heights in fiscal year 2013 with respect to industry partnerships, collaborations and licenses. 34 license and option agreements were executed, an increase of 13 percent over FY12, and 29 corporate sponsored and collaboration research agreements were executed, an increase of 45 percent over FY12. The report highlights selected licenses and collaborations, Technology Development Fund award winners, and selected technologies available for licensing.